Iktos Collaboration with Ono to Develop Innovative Therapies Against Diseases and Pain Using AI Technology
Shots:
- Iktos to receive research funding & is eligible to receive additional fees upon achievement of milestones. ONO will obtain exclusive rights globally to develop & commercialize small molecule compounds
- The collaboration will use Iktos' de novo ligand & structure-based generative modeling technologies & software Makya (AI-based retrosynthesis analysis) along with planning tool Spaya to enable the exploration of chemical space & produces innovative molecule designs with optimized properties
- The collaboration will complement Ono’s drug discovery capabilities to identify pre-clinical candidates & an additional novel chemical matter with suitable properties for undisclosed drug discovery programs
Ref: Businesswire | Image: Iktos
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.